GCG and Hepatic fibrosis: Trials with incretin coagonists have shown dramatic reductions in body weight and fat, and improvement in cardiovascular outcomes, and now semaglutide is being evaluated for improvement of liver fibrosis in MASH and moderate to advanced liver fibrosis (stage or 2 or 3) in the phase II ESSENCE trial [120].